Trump Demands US Drug Price Cuts, Sparking Pharma Stock Slump

Trump's Drug Pricing Demands

• 🇺🇸 President Trump has sent letters to 17 major drugmakers demanding immediate price cuts for drugs sold to Medicaid.
• 🌍 He also insists that new medicines be launched and maintained at prices comparable to those in wealthy overseas nations, using a policy called Most Favored Nations.
• ⏳ Companies have been given 60 days to comply voluntarily, with threats of using "every tool in our arsenal" if they do not.

Industry Reaction and Analysis

• 📉 European pharmaceutical stocks, including Novo Nordisk, AstraZeneca, and GSK, experienced significant slumps following the announcement.
• ⚖️ Analysts have expressed skepticism about the legal basis for these demands, suggesting they may be difficult to enforce and could be legally challenged.
• 💡 The White House's focus is on the price differential between the U.S. and other countries, rather than directly lowering out-of-pocket costs for American patients.

Potential Company Responses

• 🤝 Some companies may offer ornamental price cuts or direct-to-consumer channels to appease the administration.
• 💊 Examples include Eli Lilly and Novo Nordisk offering discounts on GLP-1 weight loss medicines and Pfizer/Bristol-Myers Squibb on Eliquis.
• ⚠️ However, these actions may not represent a fundamental shift, as they often affect a small percentage of patients or are already part of existing discount programs.

Broader Industry Concerns

• 🔬 The pharmaceutical industry argues that globally linked prices could undermine US biomedical research and innovation.
• 🗣️ Industry groups, like PhRMA, advocate for addressing pharmacy benefit middlemen instead of implementing foreign price controls.
• 🇨🇳 There's a concern that such policies could lead to the US losing ground in biopharmaceutical leadership to countries like China.